
Opinion|Videos|February 9, 2026
How Subcutaneous Amivantamab Fits into EGFR-Mutated NSCLC Management
Author(s)Narjust Florez, MD
PALOMA-3: subcutaneous amivantamab matches IV levels, slashes infusion reactions and steroids, and shortens clinic time.
Advertisement
Episodes in this series

Narjust Florez, MD, discusses how amivantamab and hyaluronidase-lpuj (Rybrevant Faspro; subcutaneous amivantamab) could be incorporated into routine care for patients with EGFR-mutated non–small cell lung cancer (NSCLC). Florez outlines practical considerations, including time in chair, resource utilization, and patient convenience, that may influence adoption in oncology practice. She also considers how this formulation could ultimately impact the use of the intravenous formulation.
Advertisement
Related to this article

The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.

The FDA removed the PCNSL limitation of use from the liso-cel label in LBCL, making it the second CAR T-cell therapy with this update.

Quality Improvement and EGFR-Mutant Lung Cancer Survivorship Research Help Shape Fellowship Training
Christine Ann Garcia, MD, MPH, discusses error review in fellowship training, survivorship in EGFR+ lung cancer, and nontraditional career paths.

Sanjiv Gangaram-Panday, MD, PhD, discusses 5-year SANO outcomes, distant dissemination, and next steps for active surveillance in esophageal cancer.

Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.

The FDA accepted an sNDA for selinexor plus ruxolitinib in myelofibrosis, with a target action date of June 28, 2027.

The FDA has approved neladalkib for previously treated, ALK-positive, locally advanced or metastatic non-small cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma
2
FDA Accepts sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis
3
Beyond the Target: Payloads, Therapeutic Windows, and Biomarkers Shape the Next Wave of ADCs in NSCLC
4
Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLC
5

